Meet the Neighbors — Public Health
These profiles are illustrative composites. The numbers — the Braidwood SCOTUS resolution preserving USPSTF preventive services, the Murphy preliminary injunction restoring the pre-January 2026 federal childhood schedule, the chain of three Trump EOs on environmental justice and the closure of the EPA Office of EJ, the IRA Round 1 Medicare drug pricing effective January 1, 2026, the FQHC § 330 mandatory funding extended through December 2026, the Philadelphia overdose-deaths decline from 1,376 in 2022 to 747 preliminary in 2025, the Kensington supply chemistry shift to "demon" (medetomidine 83% by March 2025) — are derived from current law, court orders, and verified primary reporting applied to documented PA-3 conditions. The neighborhoods are real and their statistical character is real. The people are constructed to make the structural patterns visible at the scale of a household or a patient. They have no names and are not based on any identifiable individual. They are devices for seeing what the federal-state-local public-health architecture produces for a constituent at a specific address — and what the next several federal court decisions, budget cycles, and rulemaking actions will mean for constituents like these.
Filter the profiles
Showing 21 of 21 profiles
North Philadelphia family in CDC ISD-supported equity zone, now defunded
North/Northwest Philadelphia Core
Household with school-age children · parental hesitancy or scheduling difficulty around routine childhood immunization · school-entry compliance check has surfaced an immunization gap
The family historically would have been engaged by PDPH outreach work supported by federal CDC Immunization Services Division and Partnership and Vaccine Equity Branch capacity-building. That federal-layer support was terminated in August 2025 after the Rhode Island injunction's August 12, 2025 narrowing excluded CDC ISD from injunction protection. PDPH absorbs the capacity loss with its own outreach infrastructure. School-entry compliance is governed by 28 Pa. Code § 23.83; the underlying immunization is recommended on the post-Murphy-restored pre-January 2026 federal schedule. The compliance pathway operates; the outreach engagement that historically supported family decision-making is structurally degraded.
Read the full Public Health Infrastructure & Governance analysis →
West Philadelphia family seeking VFC vaccine access under PPHF uncertainty
West Philadelphia Core
Low-income household · one or more children eligible for federal Vaccines for Children program (Medicaid-enrolled, uninsured, or AI/AN)
VFC was authorized through the National Childhood Vaccine Injury Act of 1986 and is funded through PHSA § 317. The CDC Immunization Program receives PPHF transfers; FY24 PPHF transfer to the CDC Immunization Program was $681.93 million. FY26 PPHF status is partially unverified, with elimination proposed in the Trump FY26 budget. VFC access is statutorily protected; the household receives the vaccine; multi-year uncertainty about funding stability is the operative concern at the policy level.
Read the full Public Health Infrastructure & Governance analysis →
PA-3 community in a PHEP-funded emergency-preparedness scenario
Citywide (illustrated through any sub-area)
Infectious disease outbreak, environmental incident, or mass-casualty event · PDPH emergency response activated
PDPH emergency response capacity is funded substantially through CDC PHEP cooperative agreements (PHSA § 247b). FY26 PHEP/ELC PA and Philadelphia direct allocations are partially unverified; PDPH FY26 budget actuals are also unverified. Emergency response operates within current PDPH capacity; multi-year exposure to PHEP funding fluctuation is the operative concern.
Read the full Public Health Infrastructure & Governance analysis →
North Philadelphia family on Murphy-restored federal schedule
North/Northwest Philadelphia Core
Household with school-age children · uses VFC vaccine pathway through pediatric provider participating in VFC
Between January 5, 2026 and March 16, 2026, the federal recommendation status of seven vaccines (rotavirus, meningococcal, hep A, hep B, flu, COVID, RSV) was demoted by the CDC Decision Memo to "shared clinical decision making." After Murphy's March 16, 2026 preliminary injunction (D. Mass., Judge Brian E. Murphy), the pre-January 2026 federal schedule is restored — approximately ten weeks of disruption. The household's pediatric vaccinations are recommended on the restored schedule; the First Circuit appeal could alter the pathway; PA continues to operate under 28 Pa. Code Chapter 23 Subchapter C without divergent state posture.
West Philadelphia PrEP user under Braidwood-preserved coverage
West Philadelphia Core
Adult resident · HIV pre-exposure prophylaxis prescription via ACA-compliant insurance plan or Medicaid managed care
USPSTF Grade A recommendation for PrEP among at-risk individuals → ACA § 2713 mandate → no-cost-sharing coverage at participating pharmacy. Kennedy v. Braidwood Management, Inc., 606 U.S. 748 (June 27, 2025) resolved 6-3 to uphold the mandate nationwide; the RFRA exemption was remanded for plaintiff-specific application; the broader mandate stands. The user accesses PrEP without cost-sharing — the most consequential single positive event for PA-3 preventive-services access in the verification window.
PA-3 resident at a PDPH HIV Prevention Cooperative Agreement site
Citywide (illustrated through North/Northwest Core)
Adult resident · HIV-prevention-relevant screening need (TB, STI, HIV testing) through PDPH-supported infrastructure
Clinic visit at a PDPH-affiliated or AACO-supported site. PDPH HIV Prevention Cooperative Agreement provides direct CDC funding for prevention infrastructure; AACO Ryan White Part A provides treatment services for people with HIV. FY26 allocation is partially unverified at the sub-domain level. Screening proceeds within current PDPH capacity; FY26 funding fluctuation is the operative concern at the policy level.
North Philadelphia pregnant constituent on Braidwood-preserved perinatal services
North/Northwest Philadelphia Core
Pregnant adult · ACA-compliant insurance or Medicaid managed care coverage
Prenatal visit at a participating obstetric provider. ACA § 2713 plus USPSTF perinatal recommendations triggers no-cost-sharing for gestational diabetes screening, perinatal depression screening, breastfeeding support counseling, and the other USPSTF A/B perinatal services. Braidwood resolved June 27, 2025; the mandate is upheld nationwide. The protection had been at risk for the ten months between the Fifth Circuit's Braidwood ruling and the SCOTUS resolution; that risk is now closed.
Citywide low-income family using Title V MCH services through PDPH MCFH
Citywide (illustrated through West Philadelphia Core)
Low-income family · young child or pregnant family member · PDPH MCFH home-visiting or perinatal-coordination program
Title V flow: HRSA-MCHB → PA DOH → PDPH MCFH → service delivery. The family enrolls in the program. FY26 PA Title V allotment is partially unverified; FY26 MCFH sub-allocation is partially unverified. FY26 funding fluctuation is the operative concern at the policy level; the federal annual-appropriation process is the operative mechanism for the gap.
PA-3 newborn through PA Newborn Screening Program
Citywide · framework is statewide
PA-3 newborn at routine post-birth screening point · screening framework is statewide
Mandatory PA Newborn Screening Program panel under 28 Pa. Code § 28.4. PDPH MCFH coordinates Philadelphia case management for abnormal results. The newborn receives the screening panel; abnormal results trigger follow-up through MCFH. Statutory framework is operative; operational continuity is not in question.
North Philadelphia Medicare beneficiary using IRA Round 1 drug
North/Northwest Philadelphia Core
Medicare-eligible adult · cardiovascular disease (atrial fibrillation; Eliquis) or type-2 diabetes with cardiovascular comorbidity (Jardiance) · enrolled in Medicare Part D (non-LIS or LIS)
Round 1 prices effective January 1, 2026. CMS MFP publication → Part D plan formulary integration → pharmacy dispensing at MFP-anchored cost-sharing under the defined-standard benefit design. Round 1 negotiated discounts range 38% to 79%; CMS projects approximately $1.5 billion aggregate beneficiary OOP savings; ASPE indicates approximately 13% of non-LIS and approximately 18% of LIS Medicare enrollees used at least one Round 1 drug in 2022. Per-fill cost-sharing drops materially under MFP-anchored pricing; aggregate beneficiary savings are bounded by the share of beneficiaries actually using the 10 selected drugs.
Citywide PA-3 patient on Braidwood-preserved USPSTF cancer screening
Citywide (illustrated through Northwest Philadelphia)
ACA-compliant-insured adult · eligible for USPSTF A/B-recommended cancer screenings (cervical 21-65, colorectal 45-75, lung 50-80 with smoking history, breast 40-74)
Primary-care visit with screening order under USPSTF guidelines. ACA § 2713 plus USPSTF A/B → no-cost-sharing for in-network screening → diagnosis or treatment pathway if abnormal. Braidwood resolved June 27, 2025; the mandate is upheld nationwide. The patient receives the recommended screening without cost-sharing; the protection is durable post-Braidwood.
West Philadelphia patient with hypertension and diabetes at an FQHC
West Philadelphia Core
ACA-compliant-insured adult (Medicaid managed care or marketplace) · documented hypertension and type-2 diabetes · primary care at a PA-3 FQHC
Annual primary-care visit with USPSTF-recommended BP screening, A1C screening, and statin recommendation. ACA § 2713 plus USPSTF → no-cost-sharing for screening → statin prescription with formulary coverage → ongoing management. Braidwood preserves the USPSTF mandate nationwide; statin coverage continues; the patient receives no-cost-sharing screening and chronic-disease management consistent with USPSTF recommendations.
West Philadelphia resident in a documented contaminant-burden tract
West Philadelphia Core
Adult resident · pre-March-2025 EJScreen cumulative-exposure score in the upper PA-3 percentile (point-source emissions, legacy industrial proximity, mixed-use residential exposure)
The resident historically would have used EJScreen for advocacy, federal grant applications, and community organizing. EPA Office of EJ closure was announced March 12, 2025; EJScreen offline same period; Region III EJ unit closed. Current pathway must rely on Harvard or Public Environmental Data Partners reconstructions, which are not federally administered. The resident retains pre-existing PA Constitutional Article I § 27 and statutory environmental protections at the state level but loses federal-level EJ analytical capacity for advocacy, grant applications, and community organizing.
PA-3 community group facing EJ grant clawback risk
Citywide (illustrated through North/Northwest Core)
PA-3 community-based environmental organization · holds or is applying for federal EJ-related infrastructure or community-grant funding
EPA grant clawback pattern targeting EJ-related infrastructure funds is underway per Environmental Law Institute reporting (April 10, 2025). Federal grant agreement → EPA review under post-EO-chain framework → potential clawback or non-renewal. The community group faces uncertainty about active grant agreements and a reduced federal grant pipeline; substitute funding pathways through state and philanthropic channels become more important. PA-3-specific clawback instances are partially unverified at the sub-domain level; the general pattern is verified.
North Philadelphia parent navigating Philadelphia Lead Disclosure Law
North/Northwest Philadelphia Core
Parent or guardian of a young child · pre-1978 housing stock · potential lead-paint exposure
Lease signing or renewal triggers Philadelphia Lead Disclosure and Notification Law obligations; child blood-lead screening through PDPH or pediatric provider. Federal Residential Lead-Based Paint Hazard Reduction Act of 1992 plus PA Act 44 of 1994 plus the Philadelphia Lead Disclosure Law → landlord disclosure to tenant → child blood-lead surveillance through PDPH → remediation if blood lead is elevated. The parent receives statutorily required disclosure; the child receives the screening pathway; remediation depends on landlord compliance and surveillance capacity. Childhood blood-lead surveillance currency is partially unverified at the sub-domain level.
Citywide FQHC patient under post-Dec-2026 reauthorization uncertainty
Citywide (illustrated through West Philadelphia Core)
Adult PA-3 patient (Medicaid or uninsured) · primary care through a PA-3 FQHC (Philadelphia FIGHT, Puentes de Salud, MANNA, RHD, or Family Practice & Counseling Network)
Annual primary-care visit; chronic-disease management; preventive services. PHSA § 330 mandatory funding (extended through December 2026 via 2026 Consolidated Appropriations Act) plus Medicaid managed care (PA HealthChoices) plus 340B drug pricing → FQHC service delivery. No multi-year reauthorization despite advocate push; OBBBA Medicaid cuts threaten 40%+ of FQHC revenue over a multi-year horizon; CHC operating margins below -2% with under 90 days cash on hand. The patient continues to receive FQHC services in the near term; multi-year capacity faces structural pressure from federal Medicaid retrenchment and the short-term reauthorization horizon.
North Philadelphia Medicaid patient at Temple Health under FY26 capital trim
North/Northwest Philadelphia Core
Medicaid-enrolled adult · inpatient or outpatient services through Temple Health
PA HealthChoices Medicaid managed care → Temple Health → service delivery → FY26 capital plan trimmed by $10-15 million due to federal Medicaid uncertainty. Temple FY25 operating profit $22 million; investment-grade BBB rating maintained; FY26 capital $60-65 million (down from baseline); strategic investments continuing (Fox Chase oncology hires; Juniata Women & Families Hospital). The patient continues to receive Temple services with no closure-scenario trajectory. Multi-year capital and Medicaid exposure are the structural concerns.
West Philadelphia patient requiring Title VI / EO 13166 language access
West Philadelphia Core
Limited-English-proficiency adult (Spanish, Mandarin, Vietnamese, or other) · primary or specialty care at a PA-3 covered entity
Clinical encounter requiring language interpretation. Title VI Civil Rights Act of 1964 plus EO 13166 (August 11, 2000) → covered-entity language-access obligations → interpreter services or bilingual staff. Title VI / EO 13166 framework operative; OCR enforcement-posture under Trump-era civil-rights enforcement priorities partially unverified; Puentes de Salud explicitly serves Spanish-speaking population. The patient receives language-access services consistent with covered-entity obligations; enforcement-rigor variation operates as a downstream concern.
Kensington constituent on medetomidine-laced supply accessing buprenorphine
North/Northwest Philadelphia Core (Kensington area)
Adult with active opioid use disorder · exposed to "demon" (fentanyl-medetomidine ± xylazine) supply · accessing buprenorphine through MAT Act 2023-expanded prescriber base
MAT Act 2023 X-waiver elimination → Philadelphia buprenorphine prescriber base expanded from approximately 500 (2017) to approximately 1,500 (2023) → Sublocade or Brixadi long-acting injection → ongoing treatment plus harm-reduction overlay. Kensington supply March 2025 per Hochstatter et al.: fentanyl 98%, medetomidine 83%, xylazine 58%, BTMPS 25%. PA Overdose Prevention Program 2025: approximately 800,000 naloxone doses; approximately 9,500 reversals (Jan-Sep). Philadelphia overdose deaths 2025 preliminary 747 vs. 2022 peak 1,376. Substantially expanded buprenorphine access; medetomidine-withdrawal-syndrome risk and slow-healing wound burden; mortality risk reduced compared to acute-fentanyl-overdose mechanism.
PA medical cannabis patient post-DEA Schedule III and § 280E exemption
Citywide · PA Act 16 of 2016 framework
PA medical-cannabis cardholder · accessing medical cannabis through a PA-3 dispensary under PA Medical Marijuana Act (Act 16 of 2016)
DEA Schedule III Final Order signed April 22-23, 2026; Treasury / IRS § 280E guidance April 23, 2026 confirming prospective relief for the full 2026 calendar year. DEA Final Order → Treasury transition rule → PA dispensary operator becomes § 280E-exempt prospectively for 2026 → operational economics improve. Industry has over $1.6 billion in disputed § 280E positions; Trulieve alone approximately $445 million. PA does not have an adult-use program (avoiding apportionment-rule complication); retrospective relief has not yet been committed by Treasury for open tax years 2022-2025. The patient continues to access medical cannabis through a PA-3 dispensary; dispensary operator's economics improve prospectively in 2026; downstream pricing or access effects are speculative at the patient-experience level.
Kensington Wellness Court participant (Mayor Parker; January 2025 launch)
North/Northwest Philadelphia Core (Kensington area)
Adult arrested in Kensington in 2025 on substance-related charges · brought into the Kensington Wellness Court program
Arrest plus Wellness Court intake → treatment option (vs. prosecution) → outcome distribution. 217 arrested; 72 accepted treatment option; 10 completed; 1 of 10 later died of overdose; two-thirds of those who agreed have bench warrants ("we've literally had clients that, when the transport pulls up to a red light, have exited the car and ran" — Chief Defender Hudson). Annual budget $2.7 million; first dedicated director Eleni Belisonzi named October 2025. Pew Charitable Trusts 2025: 28% rate Mayor Parker's drug-crisis handling good or excellent vs. 39% not very good or not at all good. The statistical outcome distribution skews toward bench-warrant non-completion; researcher consensus suggests compulsory-treatment models do not reduce drug use.